These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

614 related items for PubMed ID: 9273075

  • 1. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
    de La Taille A, Houlgatte A, Houdelette P, Berlizot P, Fournier R, Ricordel I.
    Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
    [Abstract] [Full Text] [Related]

  • 2. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 3. The variation of percent free prostate-specific antigen determined by two different assays.
    Yang CR, Ou YC, Horng YY, Lee HS.
    Anticancer Res; 2003 Aug; 23(1B):707-11. PubMed ID: 12680171
    [Abstract] [Full Text] [Related]

  • 4. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
    Tarle M, Kraljić I.
    Anticancer Res; 1997 Aug; 17(3A):1531-4. PubMed ID: 9179191
    [Abstract] [Full Text] [Related]

  • 5. [Free/total ratio of prostate-specific antigen (PSA) for prostate cancer detection in patients with gray zone PSA level].
    Tanaka M, Murakami S, Igarashi T, Abe T, Suzuki K, Sekita N, Shimazaki J.
    Hinyokika Kiyo; 1997 Dec; 43(12):855-60. PubMed ID: 9488932
    [Abstract] [Full Text] [Related]

  • 6. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J, Raventós CX, Lorente JA, Lopez-Pacios MA, Encabo G, de Torres I, Andreu J.
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [Abstract] [Full Text] [Related]

  • 7. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 8. [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)].
    de la Taille A, Houlgatte A, Houdelette P, Berlizot P, Ramirez J, Ricordel I.
    Prog Urol; 1997 Apr 15; 7(2):240-5. PubMed ID: 9264766
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA, Oguz O, Olgun A, Seçkin B, Ilgan S, Hasimi A, Salih M, Peker F, Kutluay T.
    Ann Clin Lab Sci; 2002 Apr 15; 32(1):22-30. PubMed ID: 11848613
    [Abstract] [Full Text] [Related]

  • 10. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M.
    J Urol; 2000 Apr 15; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [Abstract] [Full Text] [Related]

  • 11. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W, Stieber P, Schmeller N, Nagel D, Hofmann K, Fateh-Moghadam A.
    Anticancer Res; 1997 Apr 15; 17(6D):4759-65. PubMed ID: 9494603
    [Abstract] [Full Text] [Related]

  • 12. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H.
    J Urol; 2004 Jan 15; 171(1):182-6. PubMed ID: 14665872
    [Abstract] [Full Text] [Related]

  • 13. The ratio of free to total prostate specific antigen: an advantageous addition in the differential diagnosis of benign hyperplasia and cancer of the prostate?
    Reiter W, Stieber P, Schmeller N, Nagel D, Jansen HM, Schambeck C, Fabricius PG, Pahl H, Mattes M, Constabel H, Fateh-Moghadam A.
    Anticancer Res; 1997 Jan 15; 17(4B):2987-91. PubMed ID: 9329582
    [Abstract] [Full Text] [Related]

  • 14. The effect of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total prostate specific antigen, and the free-to-total prostate specific antigen ratio in clinical practice.
    Collins GN, Martin PJ, Wynn-Davies A, Brooman PJ, O'Reilly PH.
    J Urol; 1997 May 15; 157(5):1744-7. PubMed ID: 9112518
    [Abstract] [Full Text] [Related]

  • 15. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
    Aus G, Becker C, Lilja H, Khatami A, Pihl CG, Hugosson J.
    Scand J Urol Nephrol; 2003 May 15; 37(6):466-70. PubMed ID: 14675918
    [Abstract] [Full Text] [Related]

  • 16. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.
    J Urol; 2001 Oct 15; 166(4):1339-42. PubMed ID: 11547069
    [Abstract] [Full Text] [Related]

  • 17. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H, Koide T, Kuriyama M, Ban Y, Deguchi T, Kawada Y.
    Hinyokika Kiyo; 1999 Jul 15; 45(7):457-61. PubMed ID: 10466060
    [Abstract] [Full Text] [Related]

  • 18. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
    Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R.
    J Urol; 2001 Sep 15; 166(3):851-5. PubMed ID: 11490232
    [Abstract] [Full Text] [Related]

  • 19. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
    Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schröder FH.
    J Urol; 1997 Jun 15; 157(6):2191-6. PubMed ID: 9146612
    [Abstract] [Full Text] [Related]

  • 20. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L, Egevad L, Ekman P, Hellström M.
    Scand J Urol Nephrol; 2007 Jun 15; 41(4):302-7. PubMed ID: 17763221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.